Literature DB >> 19476583

Appropriateness of cholesterol management in primary care by sex and level of cardiovascular risk.

Ann Hiott Barham1, David C Goff, Haiying Chen, Aarthi Balasubramanyam, Erica Rosenberger, Denise E Bonds, Alain G Bertoni.   

Abstract

A study was undertaken to ascertain the appropriateness of lipid screening and management per the Third Report of the Adult Treatment Panel National Cholesterol Education Program (ATP III) guideline in a sample of North Carolina primary care practices. Demographics, cholesterol values, and comorbid conditions were abstracted from the medical records from 60 community practices participating in a randomized practice-based trial (Guideline Adherence for Heart Health). Eligible patients were aged 21 to 84 years, seen during the baseline period of June 1, 2001, through May 31, 2003, and who were not taking lipid-lowering therapy. Multivariable logistic regression was utilized to assess whether age, sex, race/ethnicity, diabetes, cardiovascular disease, ATP III risk category, or pretreatment low-density lipoprotein (LDL) influenced treatment. Among 5031 eligible patients, 1711 (34.5%) received screening lipid profiles. Screening rates were higher with older age, diabetes, and cardiovascular disease. No large differences were seen by sex. Among patients screened (mean age, 51.6 years; 57.9% female), 76.6% were appropriately managed within 4 months. In adjusted analyses, older age was associated with less appropriate treatment (odds ratio [OR] per 5 years, 0.91; P=.01), and patients with LDL cholesterol <or=130 mg/dL (OR, 18.8; P<.001) and the low-risk group (OR, 27.5; P<.001) were more likely to be managed appropriately compared with patients with LDL >or=190 mg/dL and those at high risk. Among 375 patients eligible for drug treatment, those with LDL levels between 131 and 159 mg/dL were much less likely to be treated (OR, 0.15; P<.001) compared with those with LDL >190 mg/dL, whereas risk category did not influence treatment. The challenge facing implementation of ATP III guidelines is much greater for intermediate- and high-risk patients than for low-risk patients. (c) 2009 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19476583      PMCID: PMC2937269          DOI: 10.1111/j.1751-7141.2008.00019.x

Source DB:  PubMed          Journal:  Prev Cardiol        ISSN: 1520-037X


  29 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Assessment of hypercholesterolemia control in a managed care organization.

Authors:  R J Straka; R Taheri; S L Cooper; A W Tan; A C Smith
Journal:  Pharmacotherapy       Date:  2001-07       Impact factor: 4.705

3.  Value of recruitment strategies used in a primary care practice-based trial.

Authors:  Shellie D Ellis; Alain G Bertoni; Denise E Bonds; C Randall Clinch; Aarthi Balasubramanyam; Caroline Blackwell; Haiying Chen; Michael Lischke; David C Goff
Journal:  Contemp Clin Trials       Date:  2006-09-01       Impact factor: 2.226

4.  Quality of cholesterol screening and management with respect to the National Cholesterol Education's Third Adult Treatment Panel (ATPIII) guideline in primary care practices in North Carolina.

Authors:  Alain G Bertoni; Denise E Bonds; Susan Steffes; Eric Jackson; Lenore Crago; Aarthi Balasubramanyam; Haiying Chen; David C Goff
Journal:  Am Heart J       Date:  2006-10       Impact factor: 4.749

Review 5.  Clinical treatment of dyslipidemia: practice patterns and missed opportunities.

Authors:  S C Smith
Journal:  Am J Cardiol       Date:  2000-12-21       Impact factor: 2.778

6.  Use and monitoring of "statin" lipid-lowering drugs compared with guidelines.

Authors:  S A Abookire; A S Karson; J Fiskio; D W Bates
Journal:  Arch Intern Med       Date:  2001-01-08

7.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

Authors:  T A Pearson; I Laurora; H Chu; S Kafonek
Journal:  Arch Intern Med       Date:  2000-02-28

8.  Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium.

Authors:  David C Goff; Alain G Bertoni; Holly Kramer; Denise Bonds; Roger S Blumenthal; Michael Y Tsai; Bruce M Psaty
Journal:  Circulation       Date:  2006-02-07       Impact factor: 29.690

9.  Enhancing the quality of care for patients with coronary heart disease: the design and baseline results of the hastening the effective application of research through technology (HEART) trial.

Authors:  David C Goff; Lin Gu; Larry K Cantley; Deborah G Parker; Stuart J Cohen
Journal:  Am J Manag Care       Date:  2002-12       Impact factor: 2.229

10.  National trends in statin use by coronary heart disease risk category.

Authors:  Jun Ma; Niraj L Sehgal; John Z Ayanian; Randall S Stafford
Journal:  PLoS Med       Date:  2005-05-31       Impact factor: 11.069

View more
  10 in total

Review 1.  Statins in the primary prevention of cardiovascular disease.

Authors:  Željko Reiner
Journal:  Nat Rev Cardiol       Date:  2013-06-04       Impact factor: 32.419

2.  Results of a national survey on OTC medicines, Part 2: Do pharmacists support switching prescription agents to over-the-counter status?

Authors:  Lyne Lalonde; Ross T Tsuyuki; Eric Landry; Jeff Taylor
Journal:  Can Pharm J (Ott)       Date:  2012-03

3.  Predictors of cholesterol treatment discussions and statin prescribing for primary cardiovascular disease prevention in community health centers.

Authors:  Kunal N Karmali; Ji-Young Lee; Tiffany Brown; Stephen D Persell
Journal:  Prev Med       Date:  2016-04-16       Impact factor: 4.018

Review 4.  Screening strategies for cardiovascular disease in asymptomatic adults.

Authors:  Margaret L Wallace; Jason A Ricco; Bruce Barrett
Journal:  Prim Care       Date:  2014-03-27       Impact factor: 2.907

5.  Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.

Authors:  Zeneng Wang; Elizabeth Klipfell; Brian J Bennett; Robert Koeth; Bruce S Levison; Brandon Dugar; Ariel E Feldstein; Earl B Britt; Xiaoming Fu; Yoon-Mi Chung; Yuping Wu; Phil Schauer; Jonathan D Smith; Hooman Allayee; W H Wilson Tang; Joseph A DiDonato; Aldons J Lusis; Stanley L Hazen
Journal:  Nature       Date:  2011-04-07       Impact factor: 49.962

Review 6.  Multimorbidity and Patient Safety Incidents in Primary Care: A Systematic Review and Meta-Analysis.

Authors:  Maria Panagioti; Jonathan Stokes; Aneez Esmail; Peter Coventry; Sudeh Cheraghi-Sohi; Rahul Alam; Peter Bower
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

7.  Physicians' behavior following changes in LDL cholesterol target goals.

Authors:  Shlomo Vinker; Haim Bitterman; Doron Comaneshter; Arnon D Cohen
Journal:  Isr J Health Policy Res       Date:  2015-06-01

8.  Cohort study investigating the relationship between cholesterol, cardiovascular risk score and the prescribing of statins in UK primary care: study protocol.

Authors:  Samuel Finnikin; Ronan Ryan; Tom Marshall
Journal:  BMJ Open       Date:  2016-11-17       Impact factor: 2.692

9.  Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a national retrospective cohort study.

Authors:  Jianhua Wu; Shihua Zhu; Guiqing Lily Yao; Mohammed A Mohammed; Tom Marshall
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

10.  Statin prescription among patients with type 2 diabetes in Botswana: findings and implications.

Authors:  Julius Chacha Mwita; Brian Godman; Tonya M Esterhuizen
Journal:  BMC Endocr Disord       Date:  2020-03-10       Impact factor: 2.763

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.